Johnson & Johnson Q1 2026 Sales Reach $24.06 Billion

By Chris Stiles • Tuesday, April 14 11:01 • Permanent Link

Johnson & Johnson reported first-quarter 2026 sales of $24.06 billion, up 9.9% from $21.89 billion a year earlier.

On an operational basis, sales rose 6.4%, while adjusted operational sales increased 5.3%. Net earnings fell to $5.24 billion from $11.00 billion, and diluted earnings per share declined to $2.14 from $4.54.

Adjusted net earnings were $6.61 billion, down 1.4% from $6.71 billion, and adjusted diluted EPS slipped 2.5% to $2.70 from $2.77. Free cash flow was about $1.5 billion, down from $3.38 billion in the prior-year quarter.

By geography, U.S. sales rose 8.3% to $13.33 billion from $12.31 billion. International sales increased 11.9% to $10.73 billion from $9.59 billion. Operational growth was 8.3% in the U.S. and 3.9% internationally, while adjusted operational growth was 8.3% domestically and 4.0% abroad.

By segment, Innovative Medicine sales climbed 11.2% to $15.43 billion from $13.87 billion. Operational growth in the segment was 7.4%, and adjusted operational growth was 5.6%. MedTech sales rose 7.7% to $8.64 billion from $8.02 billion, with operational growth of 4.6% and adjusted operational growth of 4.7%.

Within Innovative Medicine, growth came from Darzalex, Carvykti, Erleada, and Rybrevant/Lazcluze in oncology, Tremfya in immunology, and Spravato in neuroscience. That was partly offset by an approximate 920-basis-point drag from Stelara and by Imbruvica. MedTech growth was driven by electrophysiology products, Abiomed, Shockwave in cardiovascular, and trauma in orthopaedics.

Johnson & Johnson raised its 2026 outlook. It now expects estimated reported sales of $100.8 billion at the midpoint, up from $100.5 billion previously, and adjusted diluted EPS of $11.55 at the midpoint, up from $11.53. The new sales midpoint implies 7.0% growth, versus 6.7% in the prior outlook, while the EPS midpoint implies 7.1% growth, versus 6.9% before.

For the full year, the company lifted its adjusted operational sales midpoint to $100.2 billion from $100.0 billion and its adjusted operational EPS midpoint to $11.40 from $11.38. Today the company's shares have moved -0.29% to a price of $239.24. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.